Azathioprine in the treatment of myasthenia gravis

A. S. Witte, David Cornblath, G. J. Parry, R. P. Lisak, N. J. Schatz

Research output: Contribution to journalArticle

Abstract

Twenty-four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.

Original languageEnglish (US)
Pages (from-to)602-605
Number of pages4
JournalAnnals of Neurology
Volume15
Issue number6
StatePublished - 1984

Fingerprint

Myasthenia Gravis
Azathioprine
Therapeutics
Muscle Weakness
Immunosuppression
Adrenal Cortex Hormones
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Witte, A. S., Cornblath, D., Parry, G. J., Lisak, R. P., & Schatz, N. J. (1984). Azathioprine in the treatment of myasthenia gravis. Annals of Neurology, 15(6), 602-605.

Azathioprine in the treatment of myasthenia gravis. / Witte, A. S.; Cornblath, David; Parry, G. J.; Lisak, R. P.; Schatz, N. J.

In: Annals of Neurology, Vol. 15, No. 6, 1984, p. 602-605.

Research output: Contribution to journalArticle

Witte, AS, Cornblath, D, Parry, GJ, Lisak, RP & Schatz, NJ 1984, 'Azathioprine in the treatment of myasthenia gravis', Annals of Neurology, vol. 15, no. 6, pp. 602-605.
Witte AS, Cornblath D, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Annals of Neurology. 1984;15(6):602-605.
Witte, A. S. ; Cornblath, David ; Parry, G. J. ; Lisak, R. P. ; Schatz, N. J. / Azathioprine in the treatment of myasthenia gravis. In: Annals of Neurology. 1984 ; Vol. 15, No. 6. pp. 602-605.
@article{8c38e0a5b75d45668b2ff912c4ba99ac,
title = "Azathioprine in the treatment of myasthenia gravis",
abstract = "Twenty-four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83{\%}) improved while receiving azathioprine; in 8 (44{\%}) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.",
author = "Witte, {A. S.} and David Cornblath and Parry, {G. J.} and Lisak, {R. P.} and Schatz, {N. J.}",
year = "1984",
language = "English (US)",
volume = "15",
pages = "602--605",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Azathioprine in the treatment of myasthenia gravis

AU - Witte, A. S.

AU - Cornblath, David

AU - Parry, G. J.

AU - Lisak, R. P.

AU - Schatz, N. J.

PY - 1984

Y1 - 1984

N2 - Twenty-four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.

AB - Twenty-four patients with myasthenia gravis were treated with azathioprine. Eighteen of the patients tolerated the drug. Six discontinued azathioprine therapy because of toxicity. Of the 18 patients, 15 (83%) improved while receiving azathioprine; in 8 (44%) improvement was felt to result solely from azathioprine. Initial response was seen after 4 to 10 months of treatment, with a mean of 6.4 months. Patients continued to improve for up to 24 months, with the mean time of peak improvement being 14 months. Relapse occurred within one year in all 6 patients in whom azathioprine administration was discontinued. Azathioprine is a reasonable alternative to corticosteroids in selected myasthenic patients requiring immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0021241991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021241991&partnerID=8YFLogxK

M3 - Article

C2 - 6742794

AN - SCOPUS:0021241991

VL - 15

SP - 602

EP - 605

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -